Concerning the clinical use of R4 RGS, Jiang et al. [78] found that downregulation of RGS2 mRNA expression is significantly correlated with poorer prognosis in CRC patients and may be involved in forming metastases that stay in line with the connection of RGS2 to the PAR4 signaling. The gene discussed is F2RL3; the disease is colorectal carcinoma.